Inside the $230 billion our new *Longevity Biotech Report* says the pipeline is already worth – no regulatory rewrite required.
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
September 28, 2026 at 9:22 AM
Inside the $230 billion our new *Longevity Biotech Report* says the pipeline is already worth – no regulatory rewrite required.
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
I’ll explore how to reliably distinguish biological aging from technical noise, and why that matters for disease prediction & intervention.
Let’s connect if you’re into aging, biotech, translational research & longevity.
#LongevityBiotech #A4LI #Aging #Epigenetics #HealthTech #Biotech
Let’s connect if you’re into aging, biotech, translational research & longevity.
#LongevityBiotech #A4LI #Aging #Epigenetics #HealthTech #Biotech
October 17, 2025 at 7:11 PM
I’ll explore how to reliably distinguish biological aging from technical noise, and why that matters for disease prediction & intervention.
Let’s connect if you’re into aging, biotech, translational research & longevity.
#LongevityBiotech #A4LI #Aging #Epigenetics #HealthTech #Biotech
Let’s connect if you’re into aging, biotech, translational research & longevity.
#LongevityBiotech #A4LI #Aging #Epigenetics #HealthTech #Biotech
Our new Longevity Biotech Report puts a number on longevity’s payoff – and asks who actually gets to cash it in.
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
September 23, 2026 at 2:19 PM
Our new Longevity Biotech Report puts a number on longevity’s payoff – and asks who actually gets to cash it in.
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
Link as first comment.
#longevity #biotech #longevitybiotech #healthspan #aging
Longevity biotech is now a market.
The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045.
Read more about it in the comment below.
Sponsored by MuseCell Innovations.
#LongevityBiotech #Biotechnology #Geroscience #Longevity
The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045.
Read more about it in the comment below.
Sponsored by MuseCell Innovations.
#LongevityBiotech #Biotechnology #Geroscience #Longevity
September 17, 2026 at 12:40 PM
Longevity biotech is now a market.
The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045.
Read more about it in the comment below.
Sponsored by MuseCell Innovations.
#LongevityBiotech #Biotechnology #Geroscience #Longevity
The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045.
Read more about it in the comment below.
Sponsored by MuseCell Innovations.
#LongevityBiotech #Biotechnology #Geroscience #Longevity
Single-gene rejuvenation target promises safer cell age reversal
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
#longevity #longevitybiotech #aging #FLFLondon2025 #FoundersForum
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
#longevity #longevitybiotech #aging #FLFLondon2025 #FoundersForum
Single-gene rejuvenation target promises safer cell age reversal
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
longevity.technology
June 9, 2025 at 5:56 PM
Single-gene rejuvenation target promises safer cell age reversal
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
#longevity #longevitybiotech #aging #FLFLondon2025 #FoundersForum
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
#longevity #longevitybiotech #aging #FLFLondon2025 #FoundersForum
🧬 EPISODE 097: Texas biotech firm Minicircle is deploying a klotho/follistatin gene therapy via offshore clinics (Honduras/Próspera, Panama, Bahamas) to bypass the lengthy FDA approval process. yellowstone-end.blogspot.com/2026/08/the-...
#LongevityBiotech #GeneTherapy #RegulatoryArbitrage
#LongevityBiotech #GeneTherapy #RegulatoryArbitrage
THE LONGEVITY ARBITRAGEMINICIRCLE, KLOTHO GENE THERAPY, AND THE OFFSHORE REGULATORY END-RUN - EPISODE 097
Texas firm Minicircle deploys klotho gene therapy via offshore clinics (Honduras, Panama) to bypass FDA. Human efficacy remains unproven...
yellowstone-end.blogspot.com
August 18, 2026 at 7:21 AM
🧬 EPISODE 097: Texas biotech firm Minicircle is deploying a klotho/follistatin gene therapy via offshore clinics (Honduras/Próspera, Panama, Bahamas) to bypass the lengthy FDA approval process. yellowstone-end.blogspot.com/2026/08/the-...
#LongevityBiotech #GeneTherapy #RegulatoryArbitrage
#LongevityBiotech #GeneTherapy #RegulatoryArbitrage
Before Longevity Biotech 2025 kicks off, I sat down with Monty Montano to talk about my journey in aging research and how bridging academia and industry can drive progress in longevity science.
#LongevityBiotech #Aging #Epigenetics #Biotech #Healthspan #Research
#LongevityBiotech #Aging #Epigenetics #Biotech #Healthspan #Research
October 20, 2025 at 6:26 PM
Before Longevity Biotech 2025 kicks off, I sat down with Monty Montano to talk about my journey in aging research and how bridging academia and industry can drive progress in longevity science.
#LongevityBiotech #Aging #Epigenetics #Biotech #Healthspan #Research
#LongevityBiotech #Aging #Epigenetics #Biotech #Healthspan #Research
Metformin steps into the vascular aging spotlight
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
#longevity #longevitybiotech
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
#longevity #longevitybiotech
Metformin steps into the vascular aging spotlight
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
longevity.technology
June 20, 2025 at 5:46 PM
Metformin steps into the vascular aging spotlight
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
#longevity #longevitybiotech
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
#longevity #longevitybiotech
New muscle-activating therapy could support healthier aging
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
#longevity #longevitybiotech
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
#longevity #longevitybiotech
New muscle-activating therapy could support healthier aging
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss
longevity.technology
July 1, 2025 at 5:42 PM
New muscle-activating therapy could support healthier aging
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
#longevity #longevitybiotech
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
#longevity #longevitybiotech
Harnessing the power of personalized cell therapy
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
#longevity #longevitybiotech #cellularregeneration #stemcells
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
#longevity #longevitybiotech #cellularregeneration #stemcells
Harnessing the power of personalized cell therapy
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
longevity.technology
March 14, 2025 at 3:10 PM
Harnessing the power of personalized cell therapy
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
#longevity #longevitybiotech #cellularregeneration #stemcells
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
#longevity #longevitybiotech #cellularregeneration #stemcells
Semaglutide linked to reduced dementia risk in 1.7 million patients
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
#longevity #longevitybiotech #dementia
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
#longevity #longevitybiotech #dementia
Semaglutide linked to reduced dementia risk in 1.7 million patients
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
longevity.technology
June 26, 2025 at 4:49 PM
Semaglutide linked to reduced dementia risk in 1.7 million patients
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
#longevity #longevitybiotech #dementia
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
#longevity #longevitybiotech #dementia
Engineered CAR immune cells show promise in Alzheimer’s
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
#longevity #longevitybiotech #alzheimers
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
#longevity #longevitybiotech #alzheimers
Engineered CAR immune cells show promise in Alzheimer’s
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
longevity.technology
June 16, 2025 at 5:37 PM
Engineered CAR immune cells show promise in Alzheimer’s
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
#longevity #longevitybiotech #alzheimers
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
#longevity #longevitybiotech #alzheimers
A topical approach to slowing systemic signs of aging
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
#longevity #longevitybiotech #supplements
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
#longevity #longevitybiotech #supplements
A topical approach to slowing systemic signs of aging
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
longevity.technology
April 21, 2025 at 4:32 PM
A topical approach to slowing systemic signs of aging
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
#longevity #longevitybiotech #supplements
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
#longevity #longevitybiotech #supplements
Coronary laser takes aim at calcified arteries in aging patients
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
#longevity #longevitybiotech
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
#longevity #longevitybiotech
Coronary laser takes aim at calcified arteries in aging patients
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
longevity.technology
June 24, 2025 at 5:53 PM
Coronary laser takes aim at calcified arteries in aging patients
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
#longevity #longevitybiotech
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
#longevity #longevitybiotech
Rubedo doses first patient in trial targeting senescent skin cells
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
#longevity #longevitybiotech #study #clinicaltrial
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
#longevity #longevitybiotech #study #clinicaltrial
Rubedo doses first patient in trial targeting senescent skin cells
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
longevity.technology
June 6, 2025 at 5:50 PM
Rubedo doses first patient in trial targeting senescent skin cells
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
#longevity #longevitybiotech #study #clinicaltrial
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
#longevity #longevitybiotech #study #clinicaltrial
Incredible breakthrough! This blend of AI and polypharmacology could revolutionize longevity biotech. Exciting to see what's next in this AI-enabled age extension journey. #AI #longevitybiotech
May 23, 2025 at 4:54 PM
Incredible breakthrough! This blend of AI and polypharmacology could revolutionize longevity biotech. Exciting to see what's next in this AI-enabled age extension journey. #AI #longevitybiotech
siRNA cell reprogramming. GPX4 senolytics in Phase 1. A4LI policy advocacy.
Session 4 at #AGE2026 — Longevity Biotech Landscape
Chair: Brenda Eap of #AllianceForLongevityInitiatives
📅 June 3 · 3:30 PM MDT
Register → bit.ly/4vDrGxG
#Geroscience #LongevityBiotech
Session 4 at #AGE2026 — Longevity Biotech Landscape
Chair: Brenda Eap of #AllianceForLongevityInitiatives
📅 June 3 · 3:30 PM MDT
Register → bit.ly/4vDrGxG
#Geroscience #LongevityBiotech
May 23, 2026 at 1:57 PM
siRNA cell reprogramming. GPX4 senolytics in Phase 1. A4LI policy advocacy.
Session 4 at #AGE2026 — Longevity Biotech Landscape
Chair: Brenda Eap of #AllianceForLongevityInitiatives
📅 June 3 · 3:30 PM MDT
Register → bit.ly/4vDrGxG
#Geroscience #LongevityBiotech
Session 4 at #AGE2026 — Longevity Biotech Landscape
Chair: Brenda Eap of #AllianceForLongevityInitiatives
📅 June 3 · 3:30 PM MDT
Register → bit.ly/4vDrGxG
#Geroscience #LongevityBiotech
Telomir-1 shows systemic age-reversal effects in rare disease model
Preclinical data suggest Telomir’s oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
#longevity #longevitybiotech #aging
Preclinical data suggest Telomir’s oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
#longevity #longevitybiotech #aging
Telomir-1 shows systemic age-reversal in rare disease model
Preclinical data suggest Telomir's oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
longevity.technology
June 6, 2025 at 5:55 PM
Telomir-1 shows systemic age-reversal effects in rare disease model
Preclinical data suggest Telomir’s oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
#longevity #longevitybiotech #aging
Preclinical data suggest Telomir’s oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
#longevity #longevitybiotech #aging
AI-designed compounds show promise in lifespan extension
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
#longevity #longevitybiotech #AI
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
#longevity #longevitybiotech #AI
AI-designed compounds show promise in lifespan extension
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
longevity.technology
May 23, 2025 at 4:54 PM
AI-designed compounds show promise in lifespan extension
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
#longevity #longevitybiotech #AI
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
#longevity #longevitybiotech #AI
From war wounds to longevity
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
#longevity #longevitybiotech #longevityeconomy
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
#longevity #longevitybiotech #longevityeconomy
From war wounds to longevity
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
longevity.technology
May 14, 2025 at 5:38 PM
From war wounds to longevity
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
#longevity #longevitybiotech #longevityeconomy
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
#longevity #longevitybiotech #longevityeconomy
‘We’re really going to need cryopreservation’
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
#longevity #longevitybiotech #cryopreservation
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
#longevity #longevitybiotech #cryopreservation
'We’re really going to need cryopreservation'
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
longevity.technology
April 28, 2025 at 6:54 PM
‘We’re really going to need cryopreservation’
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
#longevity #longevitybiotech #cryopreservation
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
#longevity #longevitybiotech #cryopreservation
M42 and Juvenescence collaborate on AI-enabled longevity drugs
Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.
#longevity #longevitybiotech #longevityinvestment
Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.
#longevity #longevitybiotech #longevityinvestment
M42 and Juvenescence collaborate on AI-enabled longevity drugs
Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.
longevity.technology
April 16, 2025 at 1:09 PM
M42 and Juvenescence collaborate on AI-enabled longevity drugs
Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.
#longevity #longevitybiotech #longevityinvestment
Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.
#longevity #longevitybiotech #longevityinvestment
Alnylam’s AMVUTTRA wins FDA nod for ATTR-related heart disease
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
#longevity #longevitybiotech
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
#longevity #longevitybiotech
Alnylam’s AMVUTTRA wins FDA nod for ATTR-related heart disease
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
longevity.technology
March 21, 2025 at 7:39 PM
Alnylam’s AMVUTTRA wins FDA nod for ATTR-related heart disease
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
#longevity #longevitybiotech
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
#longevity #longevitybiotech
Experimental drug shows promise in delaying early-onset Alzheimer’s
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
#longevity #longevitybiotech
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
#longevity #longevitybiotech
Experimental drug shows promise in delaying early-onset Alzheimer's
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
longevity.technology
March 20, 2025 at 7:10 PM
Experimental drug shows promise in delaying early-onset Alzheimer’s
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
#longevity #longevitybiotech
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
#longevity #longevitybiotech
‘Very early detection of cognitive decline is our purpose’
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
#longevity #longevitybiotech
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
#longevity #longevitybiotech
'Very early detection of cognitive decline is our purpose'
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
longevity.technology
March 18, 2025 at 7:21 PM
‘Very early detection of cognitive decline is our purpose’
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
#longevity #longevitybiotech
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
#longevity #longevitybiotech